BeOne Medicines Reports Q3 Revenue of $1.89 Billion, Raises 2026 Guidance
BeOne reported third-quarter revenue of $1.89 billion and adjusted earnings of $4.59 per ADS. It raised full-year 2026 revenue guidance to $6.9 billion-$7.0 billion.
BeOne Medicines announced its financial results for the third quarter of 2026, reporting revenue of $1.89 billion, which surpassed the FactSet consensus estimate of $1.75 billion. The company also reported adjusted earnings of $4.59 per ADS, significantly higher than the estimated $2.82. Driven by these results, the company raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion, exceeding the prior analyst estimate of $6.78 billion. CEO John V.
Oyler attributed the performance to rapid global growth and the continued success of the company's BTK inhibitor, BRUKINSA.